top biopharmaceuticals for glp-1 medication GLP-1R Agonists Weight Loss Eli Lilly Overtakes Novo Nordisk

There is a strong interest in developing obesity treatments based on glucagon-like peptide-1 (GLP-1) agonists, which have proved to limit morbidity and mortality in type 2 diabetes

Asia Pacific is expected to witness rapid growth due to expanding healthcare access and increasing awareness regarding metabolic disease management

This convenient schedule makes adherence easier compared to daily dosing, with consistent therapeutic effects throughout the week supporting continuous blood glucose regulation and weight management

February 10, 2021

GLP-1 therapy carries a risk of hypoglycemia (low blood sugar), particularly when used with other diabetes medications that lower blood glucose

Rising adoption of oral GLP-1 drugs The growing take up of oral GLP-1 medicines is, in a way, re-shaping the global GLP-1 agonists market